This site is intended for Healthcare professionals only.

Multiple vs single hyaluronic acid injection: which is more effective for knee osteoarthritis?


Multiple vs single hyaluronic acid injection: which is more effective for knee osteoarthritis?

A new meta-analysis published in the journal of BMC Musculoskeletal Disorders shows that multiple injection regimens of intra-articular hyaluronic acid (IA-HA) are safe and effective in reducing knee pain in patients with osteoarthritis (OA) without treatment-related adverse effects compared with multiple injection regimens IA saline.

Researchers performed a meta-analysis of 30 studies that assessed the effects of IA-HA in patients with knee OA vs IA saline after search on a MEDLINE and EMBASE, and PubMed databases. Mean knee pain score nearest to 3 months or 6 months, difference in pain levels, and treatment-related adverse events (AEs), and serious adverse events (SAEs) were evaluated across different dosing regimens.

The pooled results of all studies showed that IA-HA injections reduced knee pain compared with IA saline injections for all dosing regimens. 2-4 injections of IA-HA vs IA saline significantly reduced knee pain after 3-month (standard mean difference [SMD], −0.76; 95% CI, −0.98 to −0.53; P<.00001) and 6-month follow-up (SMD, −0.36; 95% CI, −0.63 to −0.09; P=.008). The single injection of IA-HA vs IA-saline did not reduce knee pain after 3-month and 6-month follow-up whereas ≥5 injections significantly reduced pain after 6-month follow-up. The risk for treatment-related AEs was higher in patient who received ≥5 injections of IA-HA compared with those who received IA saline injections (risk ratio, 1.70; 95% CI, 1.12-2.59; P=.01), which was not seen in patients who received 1 and 2-4 injections of IA-HA.

This study has provided the detailed evaluation of differences between injection regimens of IA-HA for knee pain in OA. Authors call for further research to directly compare different IA-HA injection regimens in head-to-head randomised controlled trials.

For further reference log on to:

A systematic review and meta-analysis. BMC Musculoskelet Disord. 2017 Dec 21;18(1):542. doi: 10.1186/s12891-017-1897-2. PMID: 29268731

The following two tabs change content below.
Dr. Kamal Kant Kohli

Dr. Kamal Kant Kohli

A Medical practitioner with a flair for writing medical articles, Dr Kamal Kant Kohli joined Medical Dialogues as an Editor-in-Chief for the Speciality Medical Dialogues. Before Joining Medical Dialogues, he has served as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils of India. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751
Source: BMC

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted